PAKIANATHAN DEEPIKA 4

What Happened

• Deepika Pakianathan, a director of Theravance Biopharma, was granted a total of 19,407 equity awards on 2026-06-12: 6,009 shares acquired (non-derivative) and 13,398 derivative awards (likely stock options or similar), each with an acquisition price of $0. Total reported value for both items is $0 on the Form 4 (accession 0001270734-26-000004). This is a grant/award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-12; Form 4 filed: 2026-06-16.
• Grants: 6,009 shares (non-derivative) @ $0; 13,398 derivative awards @ $0.
• Reported total cash value on the form: $0.
• Shares owned after the transaction: not disclosed in the filing.
• Footnote: F1 — the derivative option vests 1/12th per month after grant; any remaining unvested shares vest on the next annual shareholders' meeting if the optionee remains in continuous service.
• Filing timeliness: filing date is shown, but the form does not indicate a late filing flag.

Context

• The derivative award is subject to a vesting schedule (monthly vesting for 1/12th, remainder at next annual meeting per F1), so these shares/options are not immediately tradable. Grants and option awards are routine for directors and do not by themselves signal buying or selling intent in the market.